genetics

Last reviewed 08/2022

Mutation in the HFE gene located on chromosome 6 is the principle gene defect that increases the risk of developing haemochromatosis

  • this mutation causes the substitution of tyrosine for cysteine at amino acid position 282 of the protein product (C282Y)
    • account for 80%-85% of typical patients with HH
  • two more mutations have been identified - aspartate is substituted for histidine at amino acid position 63 (H63D) and cysteine is substituted for serine at amino acid position 65 (S65C)
    • are not generally associated with iron loading unless occurring as a compound heterozygote (C282Y/H63D or C282Y/ S65C) (1,2)

Other inherited forms known as non HFE related hereditary hemachromatosis (HH) encompasses all genetic hemachromatosis unrelated to HFE mutations.

  • transferrin receptor 2 (TfR2)-associated haemochromatosis
    • also called “type 3 haemochromatosis”
    • caused by mutations in the genes for transferrin receptor 2 (TfR2)
    • autosomal recessive form which is clinically similar to HFE related HH
    • may present early in life.         
  • juvenile haemochromatosis
    • also known as “type 2 haemochromatosis”
    • mutations in two different genes results in two forms of juvenile HH
      • type 2A - mutation in the hemojuvelin (HJV) gene on chromosome 1q – most common form
      • type 2B - mutations in the hepcidin gene (HAMP) 
  • mutations in the genes for ferroportin (SLC40A1)
    • improperly called “type 4 haemochromatosis”
    • inherited in a dominant fashion (1,2)

Reference: